1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-I-yl) ureas as P38 mapkinase inhibitors

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9850231
APP PUB NO 20160009695A1
SERIAL NO

14795957

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

There is provided a compound of formula (I) which is an inhibitor of the family of p38 mitogen-activated protein kinase enzymes, and to its use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
JANSSEN PHARMACEUTICA NVBEERSE

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Broeckx, Rudy Beerse, BE 5 107
Charron, Catherine Elisabeth London, GB 28 838
Copmans, Alex Beerse, BE 5 107
Filliers, Walter Beerse, BE 5 107
Ito, Kazuhiro Wallington, GB 180 1753
King-Underwood, John Pendock, GB 45 988
Longshaw, Alistair Ian Nottingham, GB 21 301
Onions, Stuart Thomas Nottingham, GB 70 1138

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jun 26, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jun 26, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00